Overview

Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis

Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for lesion reduction will be defined as statistically greater mean percent reductions at week six in the dapsone gel-treated extremity compared with the control extremity of each patient.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Treatments:
Dapsone